These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 19038046)

  • 1. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
    Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
    BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
    Baker CH; Solorzano CC; Fidler IJ
    Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
    Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
    Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
    Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
    Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
    Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
    Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
    Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
    Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
    Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
    Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model.
    Zhou S; Yang Y; Yang Y; Tao H; Li D; Zhang J; Jiang G; Fang J
    PLoS One; 2013; 8(7):e68589. PubMed ID: 23874680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
    Lang SA; Schachtschneider P; Moser C; Mori A; Hackl C; Gaumann A; Batt D; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2008 Nov; 7(11):3509-18. PubMed ID: 19001434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
    Abdelrahim M; Baker CH; Abbruzzese JL; Safe S
    J Natl Cancer Inst; 2006 Jun; 98(12):855-68. PubMed ID: 16788159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
    Zhang X; Galardi E; Duquette M; Lawler J; Parangi S
    Clin Cancer Res; 2005 Aug; 11(15):5622-30. PubMed ID: 16061881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
    Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
    Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGF-C ShRNA inhibits pancreatic cancer growth and lymphangiogenesis in an orthotopic fluorescent nude mouse model.
    Shi Y; Tong M; Wu Y; Yang Z; Hoffman RM; Zhang Y; Tian Y; Qi M; Lin Y; Liu Y; Dai L; Sun Y; Wang Z
    Anticancer Res; 2013 Feb; 33(2):409-17. PubMed ID: 23393331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
    Yapp DT; Wong MQ; Kyle AH; Valdez SM; Tso J; Yung A; Kozlowski P; Owen DA; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Ng SS
    Angiogenesis; 2016 Apr; 19(2):229-44. PubMed ID: 26961182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
    McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
    Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine.
    Amoh Y; Li L; Tsuji K; Moossa AR; Katsuoka K; Hoffman RM; Bouvet M
    J Surg Res; 2006 May; 132(2):164-9. PubMed ID: 16500746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
    Casneuf VF; Demetter P; Boterberg T; Delrue L; Peeters M; Van Damme N
    Oncol Rep; 2009 Jul; 22(1):105-13. PubMed ID: 19513511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
    Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
    Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.